Medical Science Liaison - Diagnostic (East)

Overview

The Diagnostic Medical Science Liaison (MSL) is a field-based scientific expert responsible for advancing high-quality biomarker testing, diagnostic excellence, and precision-medicine readiness across oncology practices and laboratories. This role strengthens scientific partnerships with healthcare providers, pathologists, and laboratory leaders to ensure patients receive timely, guideline-aligned diagnostic testing that informs optimal therapeutic decisions.

The Diagnostic MSL plays a critical role in shaping the diagnostic ecosystem by generating insights, educating stakeholders, and driving measurable improvements in testing adoption and patient identification.

Responsibilities

Diagnostic & Laboratory Support

• Build and maintain peer to peer scientific and clinical relationships with national and regional external experts (EEs) and academic laboratories to support appropriate adoption of biomarker testing.

• Leverages technical expertise and landscape knowledge to identify relevant EEs and emerging experts for inclusion in territory plan.

• Provide scientific education on testing methodologies, assay selection, turnaround time expectations, and interpretation of biomarker results relevant to therapeutic decision-making.

• Support healthcare providers in understanding diagnostic pathways and barriers to testing, including pre-analytic variables, ordering workflows, and operational considerations.

• Collaborate with laboratory stakeholders to help bring innovative, guideline-aligned diagnostic testing into routine oncology practice.

Insight Generation & Field Medical Intelligence

• Gather, synthesize, and communicate actionable field insights related to testing practices, diagnostic workflows, treatment pathways, and the evolving biomarker landscape.

• Identify emerging trends, scientific gaps, and barriers to biomarker testing, escalating clear and timely recommendations to Medical Affairs leadership.

• Inform medical strategy, scientific education, and evidence-generation priorities through high-quality territory intelligence and real-world diagnostic insights.

Driving Measurable Impact

• Contribute to measurable improvements in biomarker testing adoption, time-to-test, and appropriate patient identification within the assigned territory.

• Translate scientific engagement into improvements across the end-to-end patient journey—from testing to diagnosis to treatment initiation.

• Demonstrate influence on testing practices and scientific understanding aligned with evolving standards of care in priority oncology indications.

• Actively support and represent Stemline at national, regional and local scientific congresses in alignment with goals and objectives

• Executes in line with annual goals and objectives expectations, and compliantly documents field activity, insights and expenses.

Qualifications

Scientific & Clinical Expertise

• Deep understanding of oncology biomarkers, molecular diagnostics, and precision-medicine principles.

• Ability to interpret complex diagnostic data, assay methodologies, and clinical evidence.

• Maintains up-to-date knowledge of evolving standards of care, guideline updates, and diagnostic innovations.

Diagnostic & Laboratory Systems Knowledge

• Expertise in laboratory workflows, pre-analytic variables, assay validation, and quality considerations.

• Understanding of diagnostic access barriers, ordering pathways, and operational constraints across diverse practice settings.

• Ability to translate laboratory processes into actionable insights for clinicians and internal stakeholders.

Scientific Communication & Education

• Skilled at delivering clear, balanced, and tailored scientific education to diverse audiences, including oncologists, pathologists, and laboratory directors.

• Ability to simplify complex diagnostic concepts while maintaining scientific rigor.

• Strong presentation, facilitation, and scientific storytelling capabilities.

Insight Generation & Strategic Thinking

• Identifies emerging diagnostic trends, unmet needs, and barriers to testing.

• Synthesizes field insights into actionable recommendations that influence medical strategy.

• Demonstrates strategic foresight in anticipating shifts in the diagnostic landscape.

Stakeholder Engagement & Relationship Leadership

• Builds strong, trust-based peer-to-peer scientific relationships with EEs, emerging experts, laboratory leaders, and multidisciplinary care teams.

• Navigates complex stakeholder environments with professionalism and scientific credibility.

• Demonstrates influence without authority to drive diagnostic excellence.

Cross-Functional Collaboration

• Works effectively with Medical Affairs, Clinical Development, Market Access, HEOR, and Commercial (within compliance boundaries).

• Provides diagnostic expertise to support internal training, strategy development, and evidence-generation initiatives.

• Acts as a bridge between field insights and internal decision-making.

Impact & Outcomes Orientation

• Utilizes strategic thinking skills and leverages technical expertise and landscape knowledge to deliver measurable impact on biomarker testing adoption, time-to-test, and patient identification.

• Connects scientific engagement to improvements across the diagnostic-to-treatment continuum.

• Uses data and insights to prioritize activities that drive meaningful patient and organizational outcomes.

Compliance & Ethical Leadership

• Models integrity and adherence to all regulatory, legal, and compliance standards.

• Ensures scientific interactions remain non-promotional and aligned with Medical Affairs governance.

• Maintains patient-centricity and scientific objectivity in all engagements.

Adaptability & Continuous Learning

• Thrives in a rapidly evolving diagnostic and therapeutic environment.

• Demonstrates resilience, curiosity, and a commitment to ongoing scientific development.

• Adapts communication and engagement strategies to diverse stakeholders and changing field dynamics.

Qualifications

• Advanced scientific degree (PhD, PharmD or MD preferred).

• Minimum 3 years prior MSL, diagnostic liaison, or laboratory experience strongly preferred.

• Deep understanding of oncology biomarkers, molecular diagnostics, and precision medicine.

• Ability to synthesize complex scientific information and communicate clearly with diverse stakeholders.

• Strong strategic thinking, relationship-building, and cross-functional collaboration skills.

• Proven ability to work independently, as well as cross-functionally with numerous internal stakeholders in a high-matrixed environment, including joint venture collaborations

• Excellent interpersonal communication and presentation skills, strong personal integrity, teamwork abilities, and a customer focus are necessary.

• Must be able to organize, prioritize, and work effectively in a constantly changing environment.

• Strong compliance knowledge and adherence to corporate compliance policies

• Current working knowledge of FDA, OIG, ICH, GCP, PhRMA Code, HIPAA and other compliance regulations and guidelines relevant to industry interactions with healthcare professionals

• Demonstrated technical acumen including MS Office skills, ability to adopt and leverage multiple business applications.

• This position will require up to 75%, including within the territory, to the home office and national meetings.

Base Salary Range of $208,000 - $245,000. Menarini Stemline offers generous compensation and benefits packages, including Short and Long-Term Incentive Programs, Fidelity 401(k) (with company match of 6%), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.